Headed to #Georgia to attend & present at the South East Lipid Research Conference! Presenting $ESPR's novel #MOA on Fri., Sept. 12. #SELRC

Enjoying my time at the South East Lipid Research Conference (#SELRC) and collaborating with fellow lipid historians!

The session entitled "New #Cardiovascular Therapies" just kicked off! My talk begins in an hour & will focus on the #MOA of #ETC1002. #SELRC

$ESPR 008 Ph 2b results confirm #LDL #cholesterol lowering by 30-40% & #hsCRP reduction by up to 40%. Check it out: bit.ly/1rKxvFe

Cumulative results of the #ETC1002 clinical development program confirm to date that it represents a real, innovative scientific advance.

#ETC1002 represents a real potential medical advance in #LDL #Cholesterol lowering. Link to Esperion Inc. 008 webcast: bit.ly/1m8MF2i

Thx to the sponsors & guest speakers for their contributions to an amazingly informative #PLMI2014 conference this past weekend in #Seattle.

ICYMI: Along w/#LDL #cholesterol lowering, #ETC1002 consistently demonstrates reduction in #hsCRP, biomarker for inflammation.

Link to NYAS for details of Dr. Sergey Filippov's New York Academy of Sciences panel presentation here: bit.ly/1tFCf1b

#ETC1002 review published in #Elsevier Athero discussing #LDL ↓ up to 32% w/beneficial effects superior to approved non-statin lipid ↓ agent

Link to piece and additional evidence here for those with subscription access: bit.ly/1vW79yj. #EsperionInc

Pics from last nights Schoolcraft College UBRI appreciation dinner w/#Schoolcraft undergrad bio research program students

Enjoyed my time spent earlier today with the @ArboretumVC group providing an $ESPR update presentation to the Technical Advisory Board.

Looking forward to my talk w/Hank Greenspan's University of Michigan students! I enjoy being a guest lecturer for the course Pills, Politics, & the Public Good.

Excited to interview w/MichBio's Strategic Planning Initiative Roadmap team to discuss how we can further grow/impact biosciences locally

Greg Steinberg & Steve Pinkosky presented “#ETC1002, a novel inhibitor of ACL for #LDL-cholesterol lowering” at #kernconference 2015.

#ETC1002 is converted to an active #ACL inhibitor (ETC-1002-CoA) by endogenous liver ACS activity.

Today's #kernconference 2015 panel on #Lipids, Inflammations and #Cardiovascular Diseases has been very educational! bit.ly/1JMcW4N

Have enjoyed hearing today all the local MI innovation MichBio's #DrugDiscoveryInMI session. We have some true talent in this great state!

Today, $ESPR announced positive top-line results from Study 4, the first results from the global, pivotal, Phase 3 program of #bempedoicacid: investor.esperion.com/releasedetail.…